Skip to main content
. 2023 Feb 23;14:1133207. doi: 10.3389/fimmu.2023.1133207

Figure 2.

Figure 2

Immune-related hepatitis and cholangitis in a 73-year-old female with metastatic melanoma of the tibia on nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) who developed grade 3 hepatitis. (A) Contrast-enhanced MRI in coronal view show hyperhemic and slightly thickened bile duct walls (arrow) and (B) MR cholangiopancreatography demonstrate bile ducts irregularities (arrows) compatible with immune-mediated cholangitis.